InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting
Go back to InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting| InferX Corporation (NASDAQ: IFRX) | Delayed: 1.92 +0.06 (3.23%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.86 | 52 Week High | $0.05 | |||
| Open | $1.88 | 52 Week Low | $0.00 | |||
| Day High | $1.98 | P/E | N/A | |||
| Day Low | $1.85 | EPS | $0.00 | |||
| Volume | 1,345,299 | |||||
| InferX Corporation (NASDAQ: IFRX) | Delayed: 1.92 +0.06 (3.23%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.86 | 52 Week High | $0.05 | |||
| Open | $1.88 | 52 Week Low | $0.00 | |||
| Day High | $1.98 | P/E | N/A | |||
| Day Low | $1.85 | EPS | $0.00 | |||
| Volume | 1,345,299 | |||||
